Results 81 to 90 of about 32,127 (239)

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin, Noa G. Holtzman, Challice L. Bonifant   +2 more
wiley   +1 more source

Bone marrow niche dysregulation in myeloproliferative neoplasms

Haematologica, 2020
The bone marrow niche is a complex and dynamic structure composed of a multitude of cell types which functionally create an interactive network facilitating hematopoietic stem cell development and maintenance.
Natalia Curto-Garcia, Claire Harrison, Donal P McLornan   +2 more
doaj   +1 more source

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG‐MESRAT study

British Journal of Haematology, EarlyView.
Summary EWOG‐MESRAT (European Working Group—Methylation Signatures and Response to Azacitidine Therapy; DRKS00007185) is an investigator‐initiated trial that studied EPIC array‐based DNA methylation patterns and next generation sequencing (NGS)‐based variant allele frequencies (VAFs) of driver mutations in peripheral blood (PB) and bone marrow (BM) of ...
Maximilian Schönung, Silvia Rathmann, Senthilkumar Ramamoorthy, Dirk Lebrecht, Thomas Klingebiel, Franco Locatelli, Karsten Nysom, Claudia Rossig, Jan Starý, Marco Zecca, Meera Patturajan, Miriam Erlacher, Brigitte Strahm, Charlotte M. Niemeyer, Daniel B. Lipka, Christian Flotho   +15 more
wiley   +1 more source

The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

British Journal of Haematology, EarlyView.
In oncological patients SIR measures like the mGPS have great impact on prognosis at starting therapy. We recorded at admission for allo‐HCT the mGPS in 2201 patients: score 0 CRP/sALB normal; score 1 CRP >10mg/dl; score 2 CRP >10mg/dl + sALB <35g/L. Multivariate analysis revealed a significant impact with a low GPS score for OS: mGPS 1 vs.
Hartmut Bertz, Jörg Sahlmann, Donald C. McMillan, Claudia Wehr, Jesus Duque‐Afonso, Kristina Maas‐Bauer, Ralph Wäsch, Julia Nikolaychuk, Christine Greil, Jann Arends, Jürgen Finke, Robert Zeiser   +11 more
wiley   +1 more source

Editorial: Membrane Processes in Erythroid Development and Red Cell Life Time

Frontiers in Physiology, 2021
Giampaolo Minetti, Anna Rita Migliaccio, Anna Rita Migliaccio, Eitan Fibach   +3 more
doaj   +1 more source

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Haematologica, 2017
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life.
Holly L. Geyer, Heidi Kosiorek, Amylou C. Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter AW te Boekhorst, Zhenya Senyak, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L Ferrari, Alessandro Rambaldi, Jan Samuelsson, Keith Cannon, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean-Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa   +51 more
doaj   +1 more source

Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

British Journal of Haematology, EarlyView.
Summary In the setting of haploidentical haematopoietic cell transplantation (HCT), post‐transplant cyclophosphamide (PTCy) has dramatically reduced the incidence of graft‐versus‐host disease (GVHD) and non‐relapse mortality. To further reduce GVHD incidence, the addition of antithymocyte globulin (ATG) to PTCy was evaluated in retrospective and non ...
Antoine Capes, Jarl E. Mooyaart, Didier Blaise, Stefania Bramanti, Mi Kwon, Mohamad Mohty, Patrice Chevallier, Jan Vydra, Péter Reményi, Edouard Forcade, Lucía López Corral, Maija Itälä‐Remes, Ali Bazarbachi, Enrico Derenzini, Jorinde D. Hoogenboom, Jürgen Kuball, Giorgia Battipaglia, Florent Malard, Annalisa Ruggeri   +18 more
wiley   +1 more source

Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity

British Journal of Haematology, EarlyView.
A proposed model of Setd2 deficiency and KrasG12D/+ mutation synergism in the pathogenesis of juvenile myelomonocytic leukaemia (JMML). KrasG12D/+ mutation instigates constitutive activation of the RAS‐ERK1/2 signalling pathway, and Setd2 ablation in the KrasG12D/+ mutant background further hyperactivates the RAS‐ERK1/2 signalling pathway, leading to ...
Gustave Munyurangabo, Linlin Zhang, Ying Zhou, Peihua Zhang, Xiao Yu, Dou Qu, Dan Yang, Xiaomin Ren, Hongwei Liu, Yonghong Wu, Guangyao Kong, Yi Yang   +11 more
wiley   +1 more source

UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)

British Journal of Haematology, EarlyView.
Summary In allogeneic haematopoietic stem cell transplantation (HSCT), important clinical decisions depend upon assessment of chimerism, including immunosuppressant dosing and donor lymphocyte infusions (DLI), which in turn can have major impacts on disease control, graft‐versus‐host disease (GVHD), immunity and ultimately patient survival.
Andrew Clark, Hazel Clouston, Kanchan Rao, Najeem Folarin, Josu De la Fuente, Angela Hamblin, Eduardo Olavarria, Debbie Richardson, Polly Talley, Victoria Potter, Justin Loke, Terri McVeigh, John Snowden   +12 more
wiley   +1 more source

Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature

Annals of Saudi Medicine, 2016
Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm. Chronic lymphocytic leukemia is a monoclonal expansion of a CD5+ CD19+ B lymphocytes.
Serdal Korkmaz, Sinan Kulakoglu, Hasan Gorkem, Bilal Aygun, Ali Cetinkaya   +4 more
doaj   +1 more source